ATYR Stock Overview
A biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
aTyr Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.29 |
| 52 Week High | US$3.80 |
| 52 Week Low | US$1.14 |
| Beta | 1.1 |
| 11 Month Change | 1.23% |
| 3 Month Change | 77.84% |
| 1 Year Change | 163.20% |
| 33 Year Change | -60.55% |
| 5 Year Change | -27.09% |
| Change since IPO | -98.78% |
Recent News & Updates
Recent updates
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
Sep 09We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully
Jul 13
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely
Feb 03Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
Oct 04Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
May 06We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate
Jan 04aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies
Sep 29aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease
Sep 13aTyr Pharma gains with FDA Fast Track status for lead asset
Aug 11We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully
May 10Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Jan 24aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis
Dec 28aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy
Sep 24Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Sep 23Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
May 22aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 25Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?
Feb 09
aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan
Jan 14ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study
Jan 04aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study
Dec 21aTyr Pharma (LIFE) Investor Presentation - Slideshow
Oct 31Shareholder Returns
| ATYR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.2% | 4.0% | 2.2% |
| 1Y | 163.2% | 18.3% | 32.6% |
Return vs Industry: ATYR exceeded the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: ATYR exceeded the US Market which returned 32.6% over the past year.
Price Volatility
| ATYR volatility | |
|---|---|
| ATYR Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ATYR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ATYR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 58 | Sanjay Shukla | www.atyrpharma.com |
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.
aTyr Pharma, Inc. Fundamentals Summary
| ATYR fundamental statistics | |
|---|---|
| Market cap | US$261.90m |
| Earnings (TTM) | -US$63.82m |
| Revenue (TTM) | US$235.00k |
1,175x
P/S Ratio-4.3x
P/E RatioIs ATYR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATYR income statement (TTM) | |
|---|---|
| Revenue | US$235.00k |
| Cost of Revenue | US$54.90m |
| Gross Profit | -US$54.66m |
| Other Expenses | US$9.15m |
| Earnings | -US$63.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | -23,261.28% |
| Net Profit Margin | -27,155.74% |
| Debt/Equity Ratio | 0% |
How did ATYR perform over the long term?
See historical performance and comparison